| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
450 |
445 |
$32K |
| 71046 |
Radiologic examination, chest; 2 views |
680 |
659 |
$18K |
| 97110 |
Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion |
258 |
137 |
$6K |
| 97140 |
Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) |
48 |
26 |
$1K |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
38 |
28 |
$183.43 |
| Q9967 |
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml |
16 |
15 |
$154.00 |
| U0005 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 |
119 |
116 |
$89.65 |
| J3490 |
Unclassified drugs |
110 |
44 |
$63.42 |
| 36415 |
Collection of venous blood by venipuncture |
14 |
14 |
$12.45 |
| 0272 |
|
76 |
65 |
$2.36 |
| G1004 |
Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program |
18 |
15 |
$0.00 |